Page 60 - Read Online

Page 18 of 18 Qin et al. Hepatoma Res 2020;6:24 I http://dx.doi.org/10.20517/2394-5079.2020.04

hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.
141. Huang ZM, Li W, Li S, Gao F, Zhou QM, et al. Cytokine-induced killer cells in combination with transcatheter arterial
chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013;36:287-93.
142. Yu X, Zhao H, Liu L, Cao S, Ren B, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of
hepatocelluar carcinoma. J Clin Immunol 2014;34:194-203.
143. Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-
derived suppressor cells in hepatocellular carcinoma. J Hepatol 2019;70:449-57.
144. Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, et al. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in
patients with primary hepatocellular carcinoma. Oncotarget 2015;6:41339-49.
145. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of
hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
146. Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, et al. Antibodies against immune checkpoint molecules restore functions of
tumor-infiltrating t cells in hepatocellular carcinomas. Gastroenterology 2017;153:1107-19.e10.
147. Mossanen JC, Kohlhepp M, Wehr A, Krenkel O, Liepelt A, et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T-
and CD4(+) T-cell-dependent control of senescence. Gastroenterology 2019;156:1877-89.e4.
148. Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma.
Cancer Immunol Res 2016;4:574-81.
149. Tan S, Xu Y, Wang Z, Wang T, Du X, et al. Tim-3 hampers tumor surveillance of liver resident and conventional NK cells by
disrupting PI3K signaling. Cancer Res 2020;80:1130-42.